Critical Outcome Technologies Inc. (“COTI”) is a biotechnology company focused on applying its proprietary computer based technology, CHEMSAS®, to identify, profile and optimize commercially viable drug candidates at the earliest stage of preclinical drug development and thereby dramatically reduce the timeline and cost of getting new drug therapies to market.

In developing its technology, COTI has focused on novel, proprietary, small molecules used to treat cancer, HIV and multiple sclerosis. The focus for cancers is on those with high morbidity and mortality, which currently have either poor or no effective therapies.

Using CHEMSAS®, the Company is developing a pipeline of highly optimized libraries of 6-

10 small molecules for specific therapy targets and plans to sell/license these libraries to interested pharmaceutical partners for human trials and further drug development. Currently, the libraries in various stages of development in the pipeline are targeted at small cell lung cancer and other cancers, HIV integrase inhibitors, acute adult leukemias, multiple sclerosis and colorectal cancer. The Company may take particularly promising individual molecules from its libraries forward for development in the pre-clinical phase of drug development. These compounds would then be available for sale, licensing or co-development with a pharmaceutical partner.

The Company is also following a collaboration strategy to use its technology for pharmaceutical partners who have their own therapy targets, which can benefit from the Company’s drug discovery technology.